



**Disclosure of Transfers of Value
in Switzerland for 2025**

Methodological Note

Methodological Note

SWITZERLAND

As a pharmaceutical company, SERVIER works in collaboration with various stakeholders including healthcare professionals, healthcare organizations and patient organizations to improve health and quality of life. Healthcare professionals and organizations provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and scientific experience. They should be remunerated for the legitimate expertise and services they provide to the industry.

Fully aligned with the objectives of the EFPIA Code of practice, SERVIER sees transparency reporting as an opportunity to demonstrate its commitment to implement, comply with and enforce the highest ethical standards.

The present document is intended to provide all methodological information relevant for interpretation of the information disclosed by SERVIER in Switzerland.

1. Definitions

1.1. Recipients of Transfers of Values

1.1.1. Healthcare Professionals (HCP)

The following definition of Healthcare Professionals is provided by the EFPIA Code of practice:

“Any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, during his or her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Europe.

For the avoidance of doubt, the definition of HCP includes: (i) any official or employee of a government agency or other organization (whether in the public or private sector) that may prescribe, purchase, supply or administer medicinal products and (ii) any employee of a Member Company whose primary occupation is that of a practicing HCP, but excludes (x) all other employees of a Member Company and (y) a wholesaler or distributor of medicinal products.”

This definition allows identifying the following professionals our Company is interacting with:

- Physicians
- Pharmacists
- Medical staff who are authorized to prescribe, deliver or use medical products for human (for instance, midwives, dental hygienists, chiropractors, rescuers, caregivers who have followed a complementary training, medical podiatrists and complementary medicine professionals)

nb: the term “*physician*” refers in this context to a professional qualified to practice medicine. Unless they are no longer registered with their Order, the transfers of Value for retired HCPs are disclosed.

1.1.2. Healthcare Organisations (HCO)

The following definition of Healthcare Organizations is provided by the EFPIA Code of practice:

“Any legal person (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organizations within the scope of the EFPIA PO Code) whose business address, place of incorporation or primary place of operation is in Europe or (ii) through which one or more HCPs provide services.”

This definition allows us to identify the following organizations our Company is interacting with:

- Hospitals,
- Healthcare institutions or clinics,
- Group medical practices,
- Clinical research organizations or equivalent service providers,
- Service provider in preclinical research,
- Universities (Medical departments),
- Foundations and charities involved in the medical domain,
- Medical or learned societies,
- Medical education companies,
- Associations of healthcare professionals.

1.1.3. Patient Organizations (PO)

The following definition of Patient Organizations is provided by the EFPIA Code of practice:

“Not-for-profit organizations (including the umbrella organizations to which they belong), mainly composed of patients and/or caregivers, that represent and/or support the needs of patients and/or caregivers.”

1.1.4. Professional Conference Organizers (PCO)

The following definition of PCO is provided by the EFPIA Code of practice:

“A company/individual specialized in the organization and management of congresses, conferences, seminars and similar events (all considered as events). Commercial companies involved in organization of travel (travel agencies) or accommodation (hotels, banqueting functions in hotels, etc.) are not considered as PCOs.”

1.2. Kind of Transfers of Values being Disclosed

1.2.1. Transfers of Values to Healthcare Professionals

Transfers of values disclosed by our Company consist of:

- Registration fees,
 - Travel and accommodation expenses,
 - Fee for services,
 - Expenses agreed on the services or consultancy contracts.
- ⇒ When provided, paid or reimbursed to Healthcare Professionals or for their benefit, either directly or indirectly.

1.2.2. Transfers of Values to Healthcare Organizations

Transfers of values disclosed by our Company consist of:

- Donations and grants,
 - Registration fees,
 - Sponsorship agreements,
 - Travel and accommodation expenses,
 - Fees for services,
 - Expenses agreed on the services or consultancy contracts.
- ⇒ When provided, paid or reimbursed to Healthcare Organisations or for their benefit, either directly or indirectly.

1.2.3. Transfers of Values related to Research and Development Activities

According to the EFPIA Code of practice, Research and Development activities correspond to activities related to the planning of conduct of:

- Non-Clinical Studies (laboratory),
- Clinical Trials,
- Non-interventional Studies (NIS) that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of HCPs specifically for the study.

All non-interventional studies that do not fall within the scope of “prospective studies”, publication is made on a nominative basis. As such, retrospective studies will be disclosed under the “consultancy / fee for services” category of the disclosure template. In case it is not possible to distinguish between prospective and retrospective non-interventional studies, the disclosure of all NIS will be on an individual basis.

1.2.4. Transfers of Values related to Patient Organizations

Transfers of Values disclosed by our Company consist of:

- Financial support
 - Significant non-financial support
 - Contracted services
- ⇒ When provided, paid or reimbursed to Patient Organizations or for their benefit, either directly or indirectly. Transfers of Values provided to Patient Organizations are disclosed on nominative basis, even when related to Research and Development activities.

1.2.5. Transfers of Values related to Professional congress organizers (PCO)

Transfers of values disclosed by our Company consist in contributions to costs related to events organized through PCO, such as:

- Registration fees;
- Travel and accommodation
- Speaker fees
- Sponsorship agreements with HCOs or with Third Parties appointed by an HCO to manage an Event.

2. Disclosure Scope

2.1. Products Concerned

The Transfers of Values related solely to activities in connection with Over-The-Counter products are out of the scope of the disclosure.

2.2. Company concerned

The information disclosed by our Company in the present country is provided on behalf of the Servier Group.

Servier is a Group of companies with affiliates in other countries that can initiate interactions with Healthcare Professionals, Healthcare Organizations, Professional Congress Organizers or Patient Organizations.

A Group process is implemented to ensure that the local disclosure includes all transfers of value provided by companies of the Servier Group, either established locally or in foreign countries, during the previous calendar year (from 1st January to 31st December).

2.3. Excluded Transfers of Values

The Transfers of Values corresponding to the following categories or provided in relation to the following activities, are not included in the disclosed information:

- Activities solely related to Over-the-counter pharmaceutical products,
- Usual conditions offered to professionals for the ordering and delivery of medications,
- Distribution of free medical samples to professionals (as part of prescriptions from competent authorities),
- Objects, general information and low-value didactic information, targeted at professionals and designed exclusively for medical or pharmaceutical activities, or used for postgraduate medical and pharmaceutical training and which, in both cases, are also useful to patients,
- Meals of appropriate and reasonable prices (beverages included). The maximum authorized amount is 150 CHF per professional per meal in Switzerland, and according to the threshold applicable to each country.

2.4. Date of Transfers of Values

As a standard rule, the date considered to prepare the disclosure corresponds to the date of the financial payment made to or for the benefit of the recipient.

Exception: when a Transfer of Value is provided in relation to the participation to an event, the date retained for the disclosure purpose will correspond to the date of the event.

2.5. Direct Transfers of Values

The disclosure includes both direct and indirect Transfers of Values provided to recipients or for their benefit. In this context:

Direct Transfers of Values are provided directly to the recipient by our Company.

2.6. Indirect Transfers of Values

Indirect Transfers of Values are provided to the recipient through a third party. In this situation, our partners are required by contract to share with our Company all information relating to

Transfers of Values to allow appropriate preparation of the disclosure. Contributions provided to Events through PCOs (organized whether through their own initiatives or at a request of an HCO – that would therefore be the direct Recipient of the Transfer of Value) must be considered as indirect Transfer of Value and be reported on an individually named basis. Transfer of Value through PCOs are reported in the name of benefiting HCO / HCP through the PCO. The full value of the Transfer of Value provided through the PCO shall not be deemed as a benefit (in cash or in kind) to the HCO as the PCO may retain a part of this amount as “service fee”.

2.7. Non-monetary Transfers of Value

- Donations to HCOs or POs can be both monetary and donations in kind.
- For significant non-financial support to POs that cannot be assigned a meaningful monetary value, the description describes the non-monetary benefit that the Patient Organization receives.

2.8. Disclosure format of Transfer of Value to Patient Organizations

For supports:

- The disclosure format includes a description of the nature of the support, the monetary value of financial support and of invoiced costs.
- For significant non-financial support that cannot be assigned a meaningful monetary value, the description describes the non-monetary benefit that the Patient Organization receives.

For contracted services: the total amount paid per Patient Organization over the Reporting Period is disclosed.

2.9. Transfers of Values in Case of Partial Attendance or Cancellation and refund

In case of cancellation of the participation or no show, the HCP/ HCO does not receive the benefit and Transfers of Value will not be disclosed.

In case of partial attendance, only the benefits received are disclosed.

2.10. Cross Border Activities

The Servier Group makes their best efforts to capture and report all Transfers of Value to HCPs, HCOs, and POs provided by the companies of the Group, either established locally or in foreign countries.

Transfers of Values initiated by foreign companies of the Group are captured for disclosure in the country where the recipient has his physical address or principal place of practice, if applicable.

2.11. Research & Development

All kind of Transfers of Value – as identified in 1.2.1. and 1.2.2. – provided to Healthcare Professionals, or Healthcare Organizations in relation with Research and Development activities are disclosed in aggregate. For Transfers of Value provided to Patient Organizations in relation to Research and Development activities, please see section 1.2. 4.

3. Specific Considerations

3.1. Country Unique Identifier Code (UCI)

The allocation of a Unique Country Identifier Code is intended to facilitate the identification of recipients at country level and to prevent confusion when several recipients have the same name.

This code is optional according to the EFPIA Code of Practice.

In the present country, the UCI corresponds to the EAN code for HCPs.

3.2. Agreements

Each collaboration initiated by the Swiss subsidiary is subject to a contract with the HCP, the HCO or PO. There is no multi-year agreement.

Only the date of each Transfer of Value, as isolated operation, is taken into consideration to prepare the reporting.

3.3. Country specificities

In accordance with local legislation, HCPs are required to contribute at least 33% to the costs of participating in events (congresses, conferences, symposia, etc.). This contribution is reduced to 20% when the HCP is still in training.

If these expenses were paid over two calendar years, the HCP's contribution is deducted in the second calendar year.

3.4. Quality checks

Before reporting, our processes endeavor to ensure that Transfers of Value made to HCPs, HCOs and POs are collected and reconciled to the best of our ability. Additional data and process monitoring may take place for quality assurance prior to reporting.

4. Data protection legal basis

4.1. Consent Collection

Consent to individual publication is collected prior to the publication through a dedicated consent form or an agreement directly integrated into the collaboration contract.

The consent expressed by the recipient (positive or negative) is deemed valid for the collaboration concerned.

In case no consent is given, or if our Company was unable to obtain a consent form duly filled by the recipient, the publication is made under the aggregate category.

Management of Consent Withdrawal

A recipient may decide to modify or withdraw his or her consent to individual publication.

In that case, the publication will be adapted to short delays in accordance with the decision taken by the recipient. Disclosed information will be updated to move the amounts from the individual information category to the aggregated information category as defined by the reporting publication template.

Management of Recipient's Request

Recipients may initiate requests related to the information being published by our Company.

All demands will be processed according to our internal procedure.

4.2. Legitimate Interests

HCO consent is not required for disclosure and transfer of values (TOVs) to HCOs are disclosed in accordance with legitimate interests. We truly believe there is a legitimate public interest in better understanding the financial relationships that covered individuals may have with the pharmaceutical industry in the interests of transparency and trust in the pharmaceutical industry.

The HCO has the right to object to processing based on legitimate interests. In case of an objection request, Servier shall seek to ensure a balance is struck between the Contractor's rights and freedoms and our legitimate interests.

5. Disclosure Financial Data

5.1. Publication Currency

The currency used for the current publication is CHF.

5.2. VAT

Financial amounts indicated in the publication are expressed VAT excluded.

5.3. Calculation Rule

For Transfers of Values involving the use of foreign currencies, amounts are converted from the initial currency to the publication currency according to the Yearly Average Exchange Rate applicable at the date of the Transfers of Value.

6. Form of Disclosure

6.1. Date of Publication

The date of publication is: 19.06.2026.

6.2. Reporting Year

The publication has been prepared in accordance with the Swiss methodological note and the requirements of Scienceindustries. The publication relates to the previous calendar year (from 1st January to 31st December).

This information will remain available on the Internet for a period of 3 years after the date of the publication.

6.3. Disclosure Platform

The publication is provided through:

<https://servier.ch/de/unsere-engagements/transparenz/> in German and English

<https://servier.ch/fr/nos-engagements/transparence/> in French and English

For Patient Organizations:

<https://servier.ch/de/unsere-engagements/folgenden-patientenorganisationen/> in German

<https://servier.ch/fr/nos-engagements/organisation-des-patients/> in French

6.4. Disclosure Language

The publication is provided in English, German and French.

June 2026